β-adrenergic blockade is associated with a reduced risk of 90-day mortality after surgery for hip fractures.
emergency treatment
femoral fractures
hip fractures
mortality
Journal
Trauma surgery & acute care open
ISSN: 2397-5776
Titre abrégé: Trauma Surg Acute Care Open
Pays: England
ID NLM: 101698646
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
06
2020
revised:
24
06
2020
accepted:
29
06
2020
entrez:
14
8
2020
pubmed:
14
8
2020
medline:
14
8
2020
Statut:
epublish
Résumé
There is a significant postoperative mortality risk in patients subjected to surgery for hip fractures. Adrenergic hyperactivity induced by trauma and subsequent surgery is thought to be an important contributor. By downregulating the effect of circulating catecholamines the increased risk of postoperative mortality may be reduced. The aim of the current study is to assess the association between regular β-blocker therapy and postoperative mortality. This cohort study used the prospectively collected Swedish National Quality Registry for hip fractures to identify all patients over 40 years of age subjected to surgery for hip fractures between 2013 and 2017 in Örebro County, Sweden. Patients with ongoing β-blocker therapy at the time of surgery were allocated to the β-blocker-positive cohort. The primary outcome of interest was 90-day postoperative mortality. Risk factors for 90-day mortality were evaluated using Poisson regression analysis. A total of 2443 patients were included in this cohort of whom 900 (36.8%) had ongoing β-blocker therapy before surgery. The β-blocker positive group was significantly older, less fit for surgery based on their American Society of Anesthesiologists classification and had a higher prevalence of comorbidities. A significant risk reduction in 90-day mortality was detected in patients receiving β-blockers (adjusted incidence rate ratio=0.82, 95% CI 0.68 to 0.98, p=0.03). β-blocker therapy is associated with a significant reduction in 90-day postoperative mortality after hip fracture surgery. Further investigation into this finding is warranted. Therapeutic study, level III; prognostic study, level II.
Sections du résumé
BACKGROUND
BACKGROUND
There is a significant postoperative mortality risk in patients subjected to surgery for hip fractures. Adrenergic hyperactivity induced by trauma and subsequent surgery is thought to be an important contributor. By downregulating the effect of circulating catecholamines the increased risk of postoperative mortality may be reduced. The aim of the current study is to assess the association between regular β-blocker therapy and postoperative mortality.
METHODS
METHODS
This cohort study used the prospectively collected Swedish National Quality Registry for hip fractures to identify all patients over 40 years of age subjected to surgery for hip fractures between 2013 and 2017 in Örebro County, Sweden. Patients with ongoing β-blocker therapy at the time of surgery were allocated to the β-blocker-positive cohort. The primary outcome of interest was 90-day postoperative mortality. Risk factors for 90-day mortality were evaluated using Poisson regression analysis.
RESULTS
RESULTS
A total of 2443 patients were included in this cohort of whom 900 (36.8%) had ongoing β-blocker therapy before surgery. The β-blocker positive group was significantly older, less fit for surgery based on their American Society of Anesthesiologists classification and had a higher prevalence of comorbidities. A significant risk reduction in 90-day mortality was detected in patients receiving β-blockers (adjusted incidence rate ratio=0.82, 95% CI 0.68 to 0.98, p=0.03).
CONCLUSIONS
CONCLUSIONS
β-blocker therapy is associated with a significant reduction in 90-day postoperative mortality after hip fracture surgery. Further investigation into this finding is warranted.
LEVEL OF EVIDENCE
METHODS
Therapeutic study, level III; prognostic study, level II.
Identifiants
pubmed: 32789190
doi: 10.1136/tsaco-2020-000533
pii: tsaco-2020-000533
pmc: PMC7394016
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e000533Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Osteoporos Int. 2019 Dec;30(12):2477-2483
pubmed: 31451838
Injury. 2016 Jan;47 Suppl 1:S25-7
pubmed: 26768285
Bone Joint J. 2018 Apr 1;100-B(4):436-442
pubmed: 29629585
J Am Geriatr Soc. 2016 Sep;64(9):1863-8
pubmed: 27295578
World J Surg. 2020 Jun;44(6):1844-1853
pubmed: 32002583
BMC Musculoskelet Disord. 2011 May 20;12:105
pubmed: 21599967
J Trauma. 2008 Apr;64(4):1061-8
pubmed: 18404076
Shock. 2016 Oct;46(4):341-51
pubmed: 27172161
Surgery. 2009 Feb;145(2):235-42
pubmed: 19167980
World J Surg. 2015 Aug;39(8):2076-83
pubmed: 25809062
Eur Heart J. 2004 Aug;25(15):1341-62
pubmed: 15288162
World J Surg. 2019 Oct;43(10):2527-2535
pubmed: 31214833
Cochrane Database Syst Rev. 2018 Mar 13;3:CD004476
pubmed: 29533470
Ann Surg. 2020 Jan;271(1):140-146
pubmed: 30048321
Circulation. 2014 Dec 9;130(24):2215-45
pubmed: 25085962
Am Surg. 2008 Sep;74(9):866-72
pubmed: 18807680
Acta Orthop. 2020 Feb;91(1):58-62
pubmed: 31635502
N Engl J Med. 2005 Jul 28;353(4):349-61
pubmed: 16049209
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Crit Care Med. 2005 Mar;33(3):654-60
pubmed: 15753760
Am J Surg. 2012 Nov;204(5):697-703
pubmed: 22578406
Geriatr Orthop Surg Rehabil. 2019 Dec 26;10:2151459319893894
pubmed: 31903295
Osteoporos Int. 2012 Sep;23(9):2239-56
pubmed: 22419370
Geriatr Orthop Surg Rehabil. 2010 Sep;1(1):6-14
pubmed: 23569656
Br J Anaesth. 2000 Jul;85(1):109-17
pubmed: 10927999
Crit Care. 2019 Sep 4;23(1):298
pubmed: 31484576